On Monday, July 3, the next meeting of the Transparency Council.
AOTMiT: Transparency Council, among others, on treatment of retinal diseases and Pompe disease
Published June 27, 2023 08:06
Źródło: AOTMiT
The agenda includes:
Preparation of positions on drug evaluation:
- Vabysmo (farycymabum) under drug program B.70 "Treatment of patients with retinal diseases (ICD-10: H35.3, H36.0)."
- Polivy (polatuzumabum vedotinum) under the drug program "Treatment of patients with B-cell lymphoma (ICD-10: C82, C83, C85)."
- Nexviadyme (avalglucosidasum alfa) under the drug program "Treatment of patients with Pompe disease (ICD-10 E 74.0)."
Preparation of a position paper on the appropriateness of granting reimbursement approval for the medicinal product Calcort (deflazacort) for the indication: nephrotic syndrome.
Preparation of an opinion on the draft health policy program of the local government unit co-financed by the EU under the ESF: "Expanding the availability of robotically assisted functional diagnosis and rehabilitation of children and young adults with cerebral palsy and other paraplegia syndromes in the Wielkopolska Region".
Preparation of an opinion on the draft health policy program of the local government unit "Health program of secondary prevention of cervical cancer based on education and detection of HPV virus by self-sampling method, implemented in the Municipality of Kobierzyce for 2023-2025".
Source: AOTMiT
